Myocardial Recovery Using Ventricular Assist Devices
Prevalence, Clinical Characteristics, and Outcomes

Marc A. Simon, MD; Robert L. Kormos, MD; Srinivas Murali, MD; Pradeep Nair, MD; Michael Heffernan, BS; John Goresan, MD; Stephen Winowich, BS, ChE; Dennis M. McNamara, MD, MS

Background—Ventricular assist devices (VADs) are important bridges to cardiac transplantation. VAD support may also function as a bridge to ventricular recovery (BTR); however, clinical predictors of recovery and long-term outcomes remain uncertain. We examined the prevalence, characteristics, and outcomes of BTR subjects in a large single center series.

Methods and Results—We implanted VADs in 154 adults at the University of Pittsburgh from 1996 through 2003. Of these implants, 10 were BTR. This included 2/80 (2.5%) ischemic patients (supported 42 and 61 days, respectively). Both subjects had surgical revascularization, required perioperative left VAD support, and were alive and transplant-free at follow up (232 and 1319 days, respectively). A larger percentage of nonischemic patients underwent BTR (8/74, 11%; age 30 ± 14; 88% female; left ventricular ejection fraction 18 ± 6%; supported 112 ± 76 days). Three had myocarditis, 4 had post-partum cardiomyopathy (PPCM), and 1 had idiopathic cardiomyopathy. Five received biventricular support. After explantation, ventricular function declined in 2 PPCM patients who then required transplantation. Ventricular recovery in the 6 nonischemic patients surviving transplant-free was maintained (left ventricular ejection fraction 54 ± 5%; follow-up 1.5 ± 0.9 years). Overall, 8 of 10 BTR patients are alive and free of transplant (follow-up 1.6 ± 1.1 years).

Conclusions—In a large single center series, BTR was evident in 11% of nonischemic patients, and the need for biventricular support did not preclude recovery. For most BTR subjects presenting with acute inflammatory cardiomyopathy, ventricular recovery was maintained long-term. VAD support as BTR should be considered in the care of acute myocarditis and PPCM. (Circulation. 2005;112[suppl I]:I-32–I-36.)

Key Words: heart-assist device ■ heart failure ■ transplantation ■ cardiomyopathy ■ myocarditis

Ventricular assist devices (VADs) have a long history as essential bridges to transplant (BTT) for patients with end-stage congestive heart failure, and more recently as long-term destination therapy for nontransplant candidates.1,2 For transplant candidates, VAD therapy can improve survival post-transplantation.3,4 Hemodynamic unloading and myocardial rest after VAD placement may lead to recovery of native cardiac function, allowing for removal of the device without cardiac transplantation.5–11 VAD support is also associated with decreases in neurohormonal activation, alterations in myocardial calcium handling, and improvement in the proinflammatory cytokine milieu.12–20 Histological analysis of the explanted heart at the time of transplantation demonstrates decreased fibrosis and myocyte size after VAD placement.16,21,22

Despite these salutary changes as a result of VAD support, the frequency of bridge to recovery (BTR) in subjects supported long term remains low. Additional data are needed to predict long-term outcomes of BTR patients and the extent to which observed ventricular recovery is sustained. The subjects most likely to benefit from a BTR strategy remain poorly defined. We sought to further define the characteristics of successful BTR patients and their long-term outcomes in a large single center series.

Methods

Study Design and Data Collection

This study was approved by the institutional review board of the University of Pittsburgh Medical Center. All subjects who underwent VAD support as intended BTT from 1996 to 2003 were prospectively reviewed. Pediatric patients and those receiving only devices designed for transient support were excluded. Subjects received 1 of 3 VAD systems: Thoratec VAD (Thoratec Corp), Novacor LVAS (World Heart Corporation), or Heartmate LVAS XVE (Thoratec Corp).

Statistical Analysis

The clinical characteristics of subjects who underwent BTR were compared with the remaining (BTT) subjects. For BTR subjects,
Results

Prevalence of BTR and Comparison With BTT
Between 1996 and 2003, a total of 161 VAD implants were performed at the University of Pittsburgh for planned long-term support. Of these, 7 were pediatric patients that were excluded from further analysis. Of the remaining 154 adult VAD implants, 10 (6.5%) were BTR, as recovery of ventricular function allowed successful removal of the device without transplantation (Figure 1). BTR patients were younger, more often female, and less likely to have ischemic cardiomyopathy when compared with the BTT patients; other measures of heart failure (HF) severity were similar between groups (Table). Additionally, BTR patients had higher serum transaminases but lower serum creatinine. Because of their very acute presentation, elevated transaminases in the BTR groups (Table). Additionally, BTR patients had higher serum transaminases but lower serum creatinine. Because of their very acute presentation, elevated transaminases in the BTR group were felt to be secondary to hepatic congestion or hypoperfusion. These values normalized after 1 month of ventricular unloading with VAD (aspartate transaminase in the BTR group improved from 568 ± 593 to 59 ± 29 U/L, \(P = 0.02\); alanine transaminase improved from 372 ± 436 to 31 ± 23 U/L, \(P = 0.04\)) and remained normal until the time of device explantation.

Support time was similar between BTR and BTT patients (100 ± 72 days, median 73, versus 125 ± 127 days, median 89, respectively). Similar percentages of patients were supported with biventricular assist devices (BTR 50% versus BTT 40%). All BTR patients had Thoratec extracorporeal devices with the exception of 1 patient who had an implantable Thoratec IVAD, reflecting the majority of female patients with a smaller body surface area precluding larger implantable pumps. The remainder of the BTT patients had either Novacor (29%), Heartmate (14%), or Thoratec (17%) VAD for support of the left ventricle only. The majority of BTR subjects were taking angiotensin-converting enzyme inhibitors (90%) and \(\beta\)-blockers (70%) at the time of explanation.

Recovery Assessment
For BTR subjects overall, recovery of function was generally seen by 1 to 2 months of support. Mean peak oxygen consumption with the VAD rate lowered to 40 bpm was 17 ± 3 mL O\(_2\) · kg\(^{-1}\) · min\(^{-1}\). All underwent hemodynamic assessment before

Baseline Characteristics

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>BTT</th>
<th>BTR</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>133</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>50 ± 12</td>
<td>34 ± 15</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Male gender, n (%)</td>
<td>103 (77%)</td>
<td>3 (30%)</td>
<td>0.003</td>
</tr>
<tr>
<td>Ischemic etiology, n (%)</td>
<td>70 (53%)</td>
<td>2 (20%)</td>
<td>0.046</td>
</tr>
<tr>
<td>Duration of heart failure, mo</td>
<td>44.0 ± 47.2</td>
<td>0.9 ± 1.1</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>NYHA class</td>
<td>3.6 ± 0.6</td>
<td>3.8 ± 0.4</td>
<td>NS</td>
</tr>
<tr>
<td>Left ventricular ejection fraction (%)</td>
<td>17 ± 8</td>
<td>14 ± 5</td>
<td>NS</td>
</tr>
<tr>
<td>Moderate or severe MR, n (%)</td>
<td>70 (53%)</td>
<td>4 (40%)</td>
<td>NS</td>
</tr>
<tr>
<td>Inotrope/pressor support, n (%)</td>
<td>124 (95%)</td>
<td>9 (90%)</td>
<td>NS</td>
</tr>
<tr>
<td>IABP support, n (%)</td>
<td>104 (78%)</td>
<td>8 (80%)</td>
<td>NS</td>
</tr>
<tr>
<td>Cardiac index, L · min(^{-1}) · m(^{-2})</td>
<td>2.01 ± 0.53</td>
<td>2.05 ± 0.85</td>
<td>NS</td>
</tr>
<tr>
<td>PCWP, mm Hg</td>
<td>27 ± 10</td>
<td>23 ± 7</td>
<td>NS</td>
</tr>
<tr>
<td>Serum sodium, mEq/L</td>
<td>133 ± 6</td>
<td>133 ± 3</td>
<td>NS</td>
</tr>
<tr>
<td>Total bilirubin, mg/dL</td>
<td>1.36 ± 0.99</td>
<td>1.37 ± 1.09</td>
<td>NS</td>
</tr>
<tr>
<td>Serum albumin, mg/dL</td>
<td>3.2 ± 0.6</td>
<td>3.0 ± 0.9</td>
<td>NS</td>
</tr>
<tr>
<td>Aspartate aminotransferase, Units/L</td>
<td>73 ± 120</td>
<td>568 ± 593</td>
<td>0.03</td>
</tr>
<tr>
<td>Alanine aminotransferase, Units/L</td>
<td>76 ± 157</td>
<td>372 ± 436</td>
<td>0.06</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>1.43 ± 0.62</td>
<td>1.01 ± 0.37</td>
<td>0.04</td>
</tr>
<tr>
<td>Creatinine clearance, mL/min</td>
<td>78 ± 30</td>
<td>102 ± 35</td>
<td>0.02</td>
</tr>
<tr>
<td>Blood urea nitrogen, mg/dL</td>
<td>29 ± 17</td>
<td>19 ± 9</td>
<td>0.07</td>
</tr>
</tbody>
</table>

Values are mean ± SD.

NYHA indicates New York Heart Association; MR, mitral regurgitation; IABP, intraaortic balloon pump; PCWP, pulmonary capillary wedge pressure.
explantation. The mean pulmonary capillary wedge pressure was 12±5 mm Hg; mean cardiac output was 4.15±1.71 L/min on minimal support (hand pump once every 10 seconds).

**BTR Cohort: Ischemic**

Overall, 10 subjects were identified as BTR. This included 2 of 80 ischemic patients (2.5%). Both ischemic BTR subjects had new-onset HF after surgical revascularization for an acute myocardial infarction and required perioperative Left ventricular assist device (LVAD) support, and were felt to be candidates for BTR because of their recent-onset of HF. Patient 1 was a 48-year-old man with an LVEF of 10% after experiencing an acute myocardial infarction and undergoing bypass surgery. Postoperatively, he was transferred to our institution on pressor support and an intra-aortic balloon pump. He was supported for 42 days with a Thoratec VAD. Patient 2 was a 52-year-old man with papillary muscle rupture and severe mitral regurgitation after acute myocardial infarction with an LVEF of 20%. He underwent mitral valve and revascularization surgery and postoperatively required extracorporeal membrane oxygenation. He was supported for 61 days with a Thoratec extracorporeal LVAD.

**BTR Cohort: Nonischemic**

A larger percentage of nonischemic patients underwent successful BTR (8 of 74, 11%). The 8 nonischemic patients in the BTR group were age 30±14 years and 88% were female, with a mean LVEF 18±6%. Etiology was acute myocarditis in 3 (38% of nonischemic BTR cohort, 33% of myocarditis cases requiring VAD), peripartum cardiomyopathy (PPCM) in 4 (50% of nonischemic BTR cohort, 44% of PPCM cases requiring VAD), and 1 had recent onset idiopathic dilated cardiomyopathy (IDCM, 12% of nonischemic BTR cohort, 3% of IDCM cases requiring VAD). Of note, histology at the time on VAD implantation revealed evidence of myocarditis in only 1 subject and nonspecific inflammation in 1 and was negative in the remaining 6. The subject with recent-onset IDCM was diagnosed with active pulmonary tuberculosis while on VAD support. This was successfully treated, and his ventricle improved and he was subsequently weaned from the device.

Five patients were supported with Thoratec biventricular assist devices and 3 with Thoratec LVAD. Mean duration of support was 112±76 days (median 91 days). The mean duration of heart failure before device implant was significantly shorter in the BTR patients compared with the nonischemic BTT patients (0.9±1.1 months, median 0.4, versus 55.5±40.4 months, median 46.0, \(P<0.0005\); Figure 2). Similar results were seen in comparison with ischemic BTT patients (duration of heart failure 30.2±36.9 months, median 16.5) or all BTT patients (duration of heart failure 44.0±47.2 months, median 31.0). BTR patients also had a smaller left ventricular end-diastolic diameter (56±11 versus 69±12 mm, \(P=0.04\)), likely reflective of the shorter duration of heart failure.

**BTR Follow-Up**

Overall, 8 of 10 BTR patients are alive and free of transplant, with a mean length of follow-up 1.6±1.1 years (median 1.5 years, range 3 months to 3.6 years). Both ischemic patients remain alive and transplant-free with follow-up of 8 months and 3.6 years (most recent LVEF 30% and 36%, respectively). Of the 8 nonischemic patients, LV function declined in 2 PPCM patients who required transplantation or repeat VAD support within 1 year. The most recent LVEF was 54±5% in the 6 nonischemic patients surviving transplant-free with follow-up of 1.5±0.9 years (median 1.5 years, range 3 months to 3.0 years).

Complete recovery of LVEF was evident before explantation in the 6 nonischemic patients surviving transplant-free, but not in the 2 patients who subsequently declined (LVEF before explantation 56±3% versus 39±2%, \(P=0.002\)). The 6 nonischemic patients surviving transplant-free maintained normal LVEF up to 3 years after explantation. The 2 ischemic patients recovered to LVEFs of 35% and 45%, respectively, before explantation. For these subjects, LVEF subsequently declined in the first month after device removal but then stabilized (Figure 3).

**Discussion**

In this study, 6.5% of all adult patients implanted with a VAD for planned long-term support recovered ventricular function sufficient for device removal. The majority of these patients were nonischemic (80% of the cohort, representing 11% of the nonischemic patients), with the etiology in most cases being acute myocarditis or PPCM. This is consistent with the multicenter experience previously reported, which suggests BTR is predominantly seen in myocarditis and acute inflammatory cardiomyopathies such as PPCM. The high degree of biventricular failure in this recovery cohort, as evidenced by the large percentage requiring biventricular support, is not apparent in previous series. The present study demonstrates that the need for biventricular support should not preclude consideration of recovery.

The current report also suggests that clinical measures of acute illness, in particular duration of symptoms and LV diameter, are potentially important predictors of recovery. This article also demonstrates the limitations of histology for predicting outcomes. The majority of BTR subjects had no evidence of inflammation on myocardial histology at the time of implant, despite a clinical history suggesting acute inflam-
matory cardiomyopathy. Though histological evidence of myocarditis may suggest a potentially reversible process, a negative biopsy seems to have little predictive value.

The current report differs from the Berlin experience, which reported successful BTR in subjects with long-standing chronic dilated cardiomyopathy.10 No chronic subject (ie, history of heart failure greater than six months) was successfully weaned in our series. This may reflect a screening bias, as acute patients are may have been examined more closely for BTR than chronic subjects. Many chronic subjects, however, underwent echocardiographic weaning studies but failed to meet recovery criteria, and this cohort of “screened” BTT subjects had a duration of HF similar to that of the remaining BTT patients who were not studied (37±39, median 35, versus 45±48 months, median 30, respectively; \( P=\text{NS} \)). The finding that BTR subjects all had short durations of symptoms is consistent with the finding in nonischemic cardiomyopathy that dynamic recovery is common in recent-onset disease23 but extremely rare in more chronic disease. In addition to optimal medical therapy for heart failure, future adjunctive treatments, such as stem cells or tissue engineering with gene therapy, will be necessary to assist myocardial recovery in long-standing chronic cardiomyopathy and allow VAD as BTR to become an option for this subset of patients.

Despite the physiological improvements evident with VAD support, the number of BTR patients is low. This may be in part due to inadequate screening. Recovery of function, as defined by improvement in LVEF, was an early phenomenon that occurred within 2 months of VAD support. Routine assessment by transthoracic echo after 1 to 2 months of support would identify all the BTR subjects in the current study and appears to be the most useful clinical tool for more generalized screening for BTR. The 2 subjects who declined after BTR in this series had significant reductions in their LVEF noted within the first month after explantation. This suggests that the recurrence of LV dysfunction after BTR is unfortunately also an early phenomenon that appears soon after device removal restores normal loading conditions.

For subjects with acute onset of inflammatory myocarditis or PPCM, VAD support allows long-term restoration of cardiac function and avoidance of transplantation. Whether VAD support is therapeutic and facilitates recovery in this subset or functions as a bridge to spontaneous innate recovery remains to be determined. As knowledge of the mechanisms of VAD-induced ventricular recovery progresses, the therapeutic role of VAD support in acute inflammatory cardiomyopathy and the appropriate timing of support needs to be more clearly defined.

The results of this retrospective study must be interpreted with caution and considered primarily hypothesis-generating. The predictive value of LV size and the limited value of histology should be revaluated prospectively in a multicenter format. In particular, the absence of BTR in more chronic subjects may reflect screening bias and needs to be better delineated prospectively in a larger series.

Conclusions
In a large single center series, VAD as BTR was seen in 6.5% overall and in 11% of nonischemic patients and was most successful with acute inflammatory cardiomyopathy or PPCM. When used in acute inflammatory cardiomyopathy or PPCM, VAD support appears to allow long-term restoration of cardiac function and the avoidance of transplantation. VAD support as BTR should be an important component of the care of acute inflammatory myocarditis.

Acknowledgments
Dr McNamara is supported by National Institutes of Health grants R01 HL75038 and K24 HL69912. Dr Simon is supported by National Institutes of Health National Research Service Award 2-T32 HL07820-06. Dr Gorcsan is supported in part by National Institutes of Health award K24 HL04503-01 and American Heart Association National Grant-in-Aid 0050587N.

Disclosure
Dr Kormos is on the medical advisory boards of Thoratec Corporation and World Heart Corporation.
References


Myocardial Recovery Using Ventricular Assist Devices: Prevalence, Clinical Characteristics, and Outcomes
Marc A. Simon, Robert L. Kormos, Srinivas Murali, Pradeep Nair, Michael Heffernan, John Gorcsan, Stephen Winowich and Dennis M. McNamara

doi: 10.1161/CIRCULATIONAHA.104.524124

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/112/9_suppl/I-32

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/